AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 31571945
Drug: Dexlansoprazole modified
RxNorm normalized name: Dexlansoprazole
DrugBank: Dexlansoprazole (DB05351)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dexlansoprazole modified release-based therapy (DACM)
Trial: 31571945
Drug: Lansoprazole-based therapy
RxNorm normalized name: Lansoprazole
DrugBank: Lansoprazole (DB00448)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lansoprazole-based therapy (Control)
Trial: 31571977
Drug: Tramadol (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tramadol (2 mg/kg bolus)
Trial: 31572288
Drug: Simulation-based training
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simulation-based training for rapid evaluation and management of acute stroke; details on dosage and duration not available.
Trial: 31573078
Drug: Subcutaneous rituximab
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Subcutaneous rituximab plus standard induction chemotherapy for DLBCL or FL for 4-7 cycles, and/or every 2 months maintenance monotherapy for FL for 6-12 cycles.
Trial: 31573746
Drug: Response-adapted therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Response-adapted therapy with rituximab, bendamustine, mitoxantrone, and dexamethasone (RBMD)
Trial: 31573980
Drug: rosuvastatin (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rosuvastatin (20 mg/d × 28 days)
Trial: 31574863
Drug: Laser meridian
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Laser meridian massage (3 times weekly for 4 weeks)
Trial: 31575939
Drug: Intravenous enzyme
RxNorm normalized name: alpha-D-galactosidase enzyme Chewable Tablet [Beano]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous enzyme replacement therapy (IV-ERT) for 2 years
Trial: 31576162
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg ibuprofen + 100 mg caffeine
Trial: 31576684
Drug: BLS-M07 (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BLS-M07 (500 mg, 1,000 mg, and 1,500 mg administered orally, 5 times a week on weeks 1, 2, 4, and 8)
Trial: 31576684
Drug: BLS-M07 (1,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BLS-M07 (1,000 mg administered orally in phase 2a)
Trial: 31578012
Drug: Rivaroxaban treatment
RxNorm normalized name: Rivaroxaban
DrugBank: Rivaroxaban (DB06228)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Rivaroxaban treatment in patients with prior ischemic stroke/TIA
Trial: 31578012
Drug: Rivaroxaban treatment
RxNorm normalized name: Rivaroxaban
DrugBank: Rivaroxaban (DB06228)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Rivaroxaban treatment in patients without prior ischemic stroke/TIA
Trial: 31578311
Drug: Gene-corrected autologous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gene-corrected autologous cell therapy (transplanted epidermal sheets measuring 5 × 7 cm)
Trial: 31578311
Drug: Gene-corrected autologous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gene-corrected autologous cell therapy
Trial: 31579027
Drug: BTG-002814 (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BTG-002814 (100 mg vandetanib) delivered transarterially, 7 to 21 days before surgery
Trial: 31579027
Drug: BTG-002814 (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BTG-002814 (100 mg vandetanib)
Trial: 31580386
Drug: nab-paclitaxel plus
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: nab-paclitaxel plus gemcitabine plus cisplatin (25 mg/m2, 37.5 mg/m2, 50 mg/m2) on days 1 and 8 of a 21-day cycle
Trial: 31582553
Drug: Yttrium-90-labeled anti-CD45
RxNorm normalized name: yttrium
DrugBank: Yttrium Y-90 (DB13076)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Yttrium-90-labeled anti-CD45 antibody followed by fludarabine and 2 Gy total body irradiation prior to hematopoietic cell transplantation
Trial: 31582673
Drug: Statin therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Statin therapy in SP group (67.5% prescribed)
Trial: 31582673
Drug: Statin therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Statin therapy in PP group (30.1% prescribed)
Trial: 31582673
Drug: Reasons for
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reasons for treatment discontinuation
Trial: 31583561
Drug: Supraphysiologic doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supraphysiologic doses of levothyroxine (L-T4)
Trial: 31584000
Drug: iCBT (internet-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: iCBT (internet-based cognitive behavioral therapy) program for 9 weeks
Trial: 31584608
Drug: Crizotinib 250
RxNorm normalized name: crizotinib 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Crizotinib 250 mg twice daily in c-MET ≥6 copies cohort
Trial: 31584608
Drug: Crizotinib 250
RxNorm normalized name: crizotinib 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Crizotinib 250 mg twice daily in c-MET mutation cohort
Trial: 31584608
Drug: Crizotinib 250
RxNorm normalized name: crizotinib 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Crizotinib 250 mg twice daily in ROS-1 translocation cohort
Trial: 31585957
Drug: Stereotactic body
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stereotactic body radiation therapy (SBRT) and selective hedgehog pathway inhibitor vismodegib
Trial: 31586664
Drug: Concurrent cetuximab
RxNorm normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Concurrent cetuximab (400 mg/m2) and intensity modulated radiation therapy with carbon ion boost
Trial: 31586757
Drug: Glembatumumab vedotin
RxNorm normalized name: Glembatumumab vedotin
DrugBank: Glembatumumab vedotin (DB05996)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glembatumumab vedotin (GV) 1.9 mg/kg/dose administered on day 1 of each 21 day cycle.
Trial: 31586998
Drug: Treatment in
RxNorm normalized name: Other agents for local oral treatment in ATC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment in patients <70 years old
Trial: 31586998
Drug: Treatment in
RxNorm normalized name: Other agents for local oral treatment in ATC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment in patients ≥70 years old
Trial: 31587882
Drug: Lazertinib (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lazertinib (20 mg, 40 mg, 80 mg, 120 mg, 160 mg, 240 mg, or 320 mg once daily continuously in 21-day cycles)
Trial: 31588493
Drug: 1 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg/kg liposomal amphotericin B
Trial: 31588493
Drug: 2 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg/kg liposomal amphotericin B
Trial: 31588493
Drug: Fixed dose
RxNorm normalized name: Humalog Mix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed dose of 300 or 500 mg liposomal amphotericin B for patients ≥100 kg
Trial: 31588567
Drug: Pomalidomide 4
RxNorm normalized name: pomalidomide 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pomalidomide 4 mg plus low-dose dexamethasone (40 mg or 20 mg for patients aged >75 years)
Trial: 31588660
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of clinical and mRNA biomarkers
Trial: 31590634
Drug: Self-report questionnaires
RxNorm normalized name: corticotropin
DrugBank: Corticotropin (DB01285)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Self-report questionnaires administered to measure cognitive complaints, fatigue, anxiety, depressive symptoms
Trial: 31591636
Drug: Endocrine Therapy
RxNorm normalized name: ENDOCRINE THERAPY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endocrine Therapy (ET) in postmenopausal patients
Trial: 31591636
Drug: Chemotherapy (CT)
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy (CT) in premenopausal patients
Trial: 31592772
Drug: Home-based aerobic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Home-based aerobic and strengthening exercises during preoperative chemotherapy or chemoradiation
Trial: 31593308
Drug: Metformin (2000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin (2000 mg/day for a minimum of 9 days, mean 13.6 days)
Trial: 31594647
Drug: ACHIM (anaerobic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACHIM (anaerobic cultivated human intestinal microbiota) administered via upper gastrointestinal route using endoscopy for 10 days
Trial: 31594667
Drug: Elbasvir/grazoprevir (EBR/GZR)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Elbasvir/grazoprevir (EBR/GZR) treatment
Trial: 31595258
Drug: Nursing care
RxNorm normalized name: Petrolatum Topical application Ointment [NURSING CARE PROTECTIVE]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nursing care intervention centered on basic self-care including twice daily walking training, privileging pre-established trips to the toilet by walking, and all daytime meals seated, off the bed.
Trial: 31595259
Drug: Intervention program
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intervention program comprising 3 weekly classes of physical exercise (45/50 min each) delivered by trained teachers after teachers' training by researchers.
Trial: 31595670
Drug: Prophylaxis treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylaxis treatment in hemophilia
Trial: 31595793
Drug: Dosage-controlled cannabis
RxNorm normalized name: Medical Cannabis
DrugBank: Medical Cannabis (DB14009)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dosage-controlled cannabis capsules; specific dosage and duration not available
Trial: 31595982
Drug: Calcimimetic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcimimetic treatment (30-60 mg daily for 4 weeks)
Trial: 31597157
Drug: Less intensive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Less intensive chemotherapy with autotransplant
Trial: 31597157
Drug: White blood
RxNorm normalized name: Human white blood cell product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: White blood cells ≥100 × 10^9/L at study entry
Trial: 31598047
Drug: Melatonin 6
RxNorm normalized name: melatonin 6 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Melatonin 6 mg sublingually as premedication
Trial: 31598139
Drug: Fingolimod 0.5
RxNorm normalized name: fingolimod 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fingolimod 0.5 mg orally once daily
Trial: 31598646
Drug: Fluzone High-Dose
RxNorm normalized name: Fluzone High-Dose
DrugBank: Influenza A virus A/Kansas/14/2017 X-327 (H3N2) antigen (formaldehyde inactivated) (DB15516)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluzone High-Dose (egg-based)
Trial: 31599928
Drug: Sodium nitrate
RxNorm normalized name: Sodium Nitrate
DrugBank: Sodium nitrate (DB15952)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium nitrate (1 g/L in drinking water for 7 days)
Trial: 31599928
Drug: Sodium nitrite
RxNorm normalized name: Sodium Nitrite
DrugBank: Nitrous acid (DB09112)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sodium nitrite (10 μmol/min infusion for 30 minutes)
Trial: 31600167
Drug: Low-dose capecitabine
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose capecitabine (150 mg bid)
Trial: 31600167
Drug: Low-dose capecitabine
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose capecitabine (300 mg bid)
Trial: 31600167
Drug: Low-dose capecitabine
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose capecitabine (450 mg bid)
Trial: 31601588
Drug: Oral glucose
RxNorm normalized name: glucose Oral Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral glucose tolerance test and insulin test at 24-28 weeks' gestation
Trial: 31601596
Drug: Oral glyburide
RxNorm normalized name: Glyburide
DrugBank: Glyburide (DB01016)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral glyburide administered within 8 hours of injury
Trial: 31601596
Drug: Oral glyburide
RxNorm normalized name: Glyburide
DrugBank: Glyburide (DB01016)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral glyburide
Trial: 31602320
Drug: FoundationACT™ ctDNA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FoundationACT™ ctDNA assay (Foundation Medicine, Cambridge, MA, USA)
Trial: 31602518
Drug: Open abdomen
RxNorm normalized name: BOTTLE OPENER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Open abdomen treatment in obese patients
Trial: 31604419
Drug: Propofol induction
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol induction dose based on total body weight (TBW) scaled by phase angle value
Trial: 31604419
Drug: Guiding propofol
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Guiding propofol induction dose according to baseline frailty score
Trial: 31604781
Drug: Blood pressure,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blood pressure, pulse wave velocity, and augmentation index measurement on two consecutive days.
Trial: 31605278
Drug: Standard split
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard split dose of 4 l polyethylene glycol for bowel preparation
Trial: 31605278
Drug: Rectal pain
RxNorm normalized name: Dermoplast Pain
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rectal pain score during defecation < 2
Trial: 31605516
Drug: Daily tips
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily tips and daily surveys from the Pocket Helper 2.0 app
Trial: 31606970
Drug: Autologous cultured
RxNorm normalized name: Autologous cultured fibroblasts
DrugBank: Azficel-T (DB11051)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Autologous cultured fibroblasts, 3 injections administered at 4-6 week intervals.
Trial: 31607268
Drug: Infliximab (IFX)
RxNorm normalized name: Infliximab
DrugBank: Infliximab (DB00065)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Infliximab (IFX) 5 mg/kg at Weeks 0, 2, and 6, with additional doses at Weeks 14 and 22 for CAI-based responders
Trial: 31612225
Drug: Combination antiretroviral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination antiretroviral therapy (cART) initiated irrespective of CD4 cell count, with a median delay in initiation decreasing from 9.07 months in 2007 to 0.77 months in 2017.
Trial: 31613328
Drug: Investigational norovirus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Investigational norovirus vaccine
Trial: 31613706
Drug: Oatmeal consumption
RxNorm normalized name: OATMEAL
DrugBank: Colloidal oatmeal (DB11286)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oatmeal consumption (2 servings of instant oatmeal daily for 2 weeks)
Trial: 31615432
Drug: Intact parathyroid
RxNorm normalized name: Intact parathyroid hormone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intact parathyroid hormone (iPTH) levels
Trial: 31615556
Drug: Floseal® treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Floseal® treatment
Trial: 31617211
Drug: Thrombocytosis (platelet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thrombocytosis (platelet count > 500 × 10^9/L)
Trial: 31617269
Drug: Tabalumab (NTC00882999)
RxNorm normalized name: Tabalumab
DrugBank: Tabalumab (DB11657)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tabalumab (NTC00882999) - a BAFF inhibitor
Trial: 31617269
Drug: Atacicept (NCT00642902)
RxNorm normalized name: Atacicept
DrugBank: Atacicept (DB06399)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atacicept (NCT00642902) - an APRIL and BAFF inhibitor
Trial: 31618421
Drug: Hourly mixed
RxNorm normalized name: Humalog Mix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hourly mixed meals providing variable protein (0.20-3.00 g·kg-1·d-1) as crystalline amino acids modeled after egg protein
Trial: 31618746
Drug: Three consecutive
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three consecutive negative values (≤0.3 (ng/mL)2/1,000)
Trial: 31618746
Drug: Emerging or
RxNorm normalized name: Medicated Pad or Tape
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Emerging or persistent strongly positive results (>2.0 (ng/mL)2/1,000)
Trial: 31618746
Drug: Test results
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test results between 0.3 and 2.0 (ng/mL)2/1,000
Trial: 31618804
Drug: Subcutaneous N8-GP
RxNorm normalized name: N8-GP
DrugBank: Turoctocog alfa pegol (DB14738)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Description: Subcutaneous N8-GP (12.5, 25, 50, or 100 IU/kg single dose in part A; 2000 IU for patients <60 kg and 4000 IU for patients ≥60 kg daily for 3 months in part B)
Trial: 31618804
Drug: Subcutaneous N8-GP
RxNorm normalized name: N8-GP
DrugBank: Turoctocog alfa pegol (DB14738)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Description: Subcutaneous N8-GP
Trial: 31619290
Drug: Rituximab-maintenance therapy
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Rituximab-maintenance therapy (375 mg/m2), 2 years duration after R-CVP treatment
Trial: 31619290
Drug: Rituximab-maintenance therapy
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Rituximab-maintenance therapy
Trial: 31619706
Drug: Carfilzomib-lenalidomide-dexamethasone (KRd)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carfilzomib-lenalidomide-dexamethasone (KRd) therapy
Trial: 31620073
Drug: Aerobic training,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aerobic training, details on dosage and duration not specified
Trial: 31620672
Drug: Legume supplement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Legume supplement providing 8.2 g/d of protein
Trial: 31620836
Drug: Appropriate antibiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Appropriate antibiotic treatment
Trial: 31620836
Drug: Inappropriate antibiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inappropriate antibiotic treatment
Trial: 31621458
Drug: Immune globulin
RxNorm normalized name: Immune Globulin
DrugBank: Human immunoglobulin G (DB00028)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immune globulin subcutaneous, human - klhw 20%
Trial: 31621477
Drug: SUPERA™ stent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SUPERA™ stent and drug-coated balloon (Passeo-18 Lux™)
Trial: 31623843
Drug: Ultra-processed food
RxNorm normalized name: Allogeneic processed thymus tissue
DrugBank: Allogeneic processed thymus tissue (DB16736)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultra-processed food consumption (average 385 g/d, 24.4% of total energy intake)
Trial: 31626037
Drug: Various treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Various treatment strategies (19 different strategies applied)
Trial: 31626649
Drug: Liquorice ingestion
RxNorm normalized name: Liquorice
DrugBank: Licorice (DB10675)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liquorice ingestion (290-370 mg/d glycyrrhizin)
Trial: 31627014
Drug: Semantic naming
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Semantic naming treatment for 12 weeks
Trial: 31627014
Drug: Patients with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients with chronic aphasia pre-treatment
Trial: 31627014
Drug: Patients with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients with chronic aphasia post-treatment
Trial: 31628118
Drug: Fast decline
RxNorm normalized name: Fast Freeze
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fast decline in eGFR (lowest quartile of eGFR slope -4.1 ml/min per 1.73 m²)
Trial: 31628118
Drug: Baseline eGFR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baseline eGFR (median 73 ml/min per 1.73 m²)
Trial: 31628130
Drug: Seven biomarkers
RxNorm normalized name: Sevenfact
DrugBank: Coagulation factor VIIa Recombinant Human (DB00036)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Seven biomarkers (NR2, NR2 antibodies, PARK7, NDKA, UFD1, B-FABP, H-FABP)
Trial: 31628667
Drug: Intradermal injection
RxNorm normalized name: Dryvax Intradermal Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intradermal injection of mixed methylene blue compound
Trial: 31628986
Drug: Laparoscopic sentinel
RxNorm normalized name: Sentinel Spectrum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Laparoscopic sentinel lymph node technique using 200 microliters of saline solution containing 37 MBq of technetium-99m nanocolloid followed by 0.5 mL of indocyanine green (ICG) injected subperitoneally.
Trial: 31628986
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of technetium-99m nanocolloid and indocyanine green (ICG) for sentinel lymph node identification
Trial: 31632154
Drug: Extended-release guaifenesin
RxNorm normalized name: guaifenesin Extended Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extended-release guaifenesin 1200 mg (Mucinex)
Trial: 31632387
Drug: Agonistic autoantibodies
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Agonistic autoantibodies (agAAb) activating the β2-adrenergic receptor
Trial: 31634407
Drug: Phrenic nerve
RxNorm normalized name: nerve growth factor
DrugBank: Nerve Growth Factor (DB12620)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phrenic nerve stimulation (PNS) therapy
Trial: 31636050
Drug: Patients with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients with lymphedema undergoing complete decongestive therapy
Trial: 31636342
Drug: Rituximab; specific
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rituximab; specific dosage and duration not available
Trial: 31637669
Drug: Olaparib (tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olaparib (tablet 100 mg bid days 3-12) combined with carboplatin (AUC 4) and paclitaxel (175 mg/m2)